Francisco Sanchez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6604276/publications.pdf

Version: 2024-02-01

1307594 1199594 14 176 7 12 citations g-index h-index papers 15 15 15 337 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 39, 101931.	2.0	5
2	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. Multiple Sclerosis and Related Disorders, 2020, 42, 102049.	2.0	4
3	New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. Neurological Research, 2020, 42, 148-152.	1.3	5
4	Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Journal of Clinical Neuroscience, 2020, 74, 65-68.	1. 5	0
5	Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy. Current Clinical Pharmacology, 2019, 14, 91-100.	0.6	16
6	SLPI in the perfusion solution helps to identify graft quality in kidney transplants. Biomarkers in Medicine, 2019, 13, 895-906.	1.4	5
7	Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. Clinical Neuropharmacology, 2019, 42, 163-166.	0.7	6
8	Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. Journal of Neurology, 2019, 266, 112-118.	3.6	12
9	Alpha Lipoic Acid: A Therapeutic Strategy that Tend to Limit the Action of Free Radicals in Transplantation. International Journal of Molecular Sciences, 2018, 19, 102.	4.1	27
10	Thalamus volume change and cognitive impairment in early relapsing–remitting multiple sclerosis patients. Neuroradiology Journal, 2018, 31, 350-355.	1.2	19
11	SLPI (secretory leukocyte peptidase inhibitor). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .	0.1	O
12	Structural sex differences at disease onset in multiple sclerosis patients. Neuroradiology Journal, 2016, 29, 368-371.	1.2	11
13	Transient Cholesterol Effects on Nicotinic Acetylcholine Receptor Cell-Surface Mobility. PLoS ONE, 2014, 9, e100346.	2.5	26
14	The Mitochondrial Complex I Activity Is Reduced in Cells with Impaired Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function. PLoS ONE, 2012, 7, e48059.	2.5	40